companies

Dark Blue Therapeutics

Founded 2020
Employees 10+
Primary contact
The Oxford Science Park
Hayakawa Building, Edmund Halley Road
OX4 4GB Oxford
United Kingdom
+44 (0) 1865 803112
Links
https://www.darkbluetx.com/
Diseases & Conditions
Sections
Dark Blue Therapeutics is an innovative drug discovery biotechnology company leveraging ground-breaking cancer biology insights from Oxford University to discover and develop innovative precision medicines that exploit novel vulnerabilities and dependencies. With this deep, proprietary understanding of target biology, Dark Blue Therapeutics matches its precision medicines to molecularly defined patient populations to develop transformative, durable drugs that address critical unmet patient needs — delivering medicines that transform the outcomes for cancer patients. It works across various biological mechanisms to identify and pursue only cancer targets with the highest transformative potential.
Founded 2020
Employees 10+
Primary contact
The Oxford Science Park
Hayakawa Building, Edmund Halley Road
OX4 4GB Oxford
United Kingdom
+44 (0) 1865 803112
Links
https://www.darkbluetx.com/
Diseases & Conditions
Sections

Funding 💰

Select investors Oxford University Innovation, Oxford Science Enterprises, Evotec

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Highly experienced team: Dark Blue Therapeutics has assembled a highly experienced team whose expertise spans the breadth of drug development from discovery to approval. This expertise has been gained over many years in the industry and draws from biotech, large pharmaceutical companies and investment management.
  • Deeply embedded in the Oxford science ecosystem: And that comes with privileged access to world-leading science and technology. The company leverages this to enable pioneering therapeutic approaches for its targets and to accelerate its drug discovery engine. In many cases, Dark Blue Therapeutics sponsors proprietary research in academic labs to take full advantage of the unique platforms its collaborators have established.
  • Exploiting the Achilles heels in cancer: Many cancers become dependent on specific biological processes or signalling pathways for growth and survival. These represent Achilles heel vulnerabilities that can be exploited with precision medicines. Dark Blue Therapeutics works closely with world leading academics to identify novel approaches to exploit these dependencies and vulnerabilities. 🔗
Last update: June 13, 2023